ESMO Congress

Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.

John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

Nicolas Girard, MD, PhD, discusses the rationale of targeting PD-L1 and LAG-3 in NSCLC in the RELATIVITY-104 study.

Angeles Alvarez Secord, MD, MHSc, discusses key takeaways from the PICCOLO trial.

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.

Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress.

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.

NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

CheckMate-9ER post hoc analysis suggests certain sugar molecules on blood proteins may predict how well niovlumab and cabozantinib in kidney cancer treatment works.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading experts.

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.

Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.

Targeted therapy, as determined by genomic profiling, outperformed standard of care in patients with pretreated metastatic cancers.

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma.

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear cell renal cell carcinoma.

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

The combination of benmelstobart with anlotinib led to efficacy improvements in patients with advanced renal cell carcinoma vs sunitinib.

Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

In a first-in-human trial, AMG 193, a drug targeting a specific mutation in tumors, showed promising results in reducing tumor size and spread in various cancers, with an acceptable safety profile.

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease control.

The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.

Non-operative management showed promising results for patients with mismatch repair proficient locally advanced rectal cancer, preserving organs without compromising survival.

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.